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Abstract: Radionuclide detection of apoptosis with of 
99mTc-Hynic-rh-Annexin V scintigraphy is an effective tool for in 
vivo visualisation and monitoring of apoptosis in various malignant tumour. Early therapy-induced increase of the tumour 
tracer uptake correlates with favourable outcome, whereas stable or decreased uptake correlates with stable disease or tumour 
progression. Therefore sequential 
99mTc-Hynic-rh-Annexin V scintigraphy could be used to predict therapy outcome on a 
patient-to-patient basis within 48 hours after the start of treatment. However, moderate tumour-to-background ratio and 
therapy-induced changes in normal tissues could confound image analysis. To assure accurate interpretation of Annexin V 
scans, the awareness of the biophysiological and biochemical properties contributing to the tracer distribution is essential. 
In with manuscript we discuss the patterns of Annexin V tumour uptake and illustrate the most frequent pitfalls associated 




Radionuclide detection of apoptosis with of 
99mTc-Hynic-rh-Annexin V scintigraphy is an effective tool 
for in vivo visualisation and monitoring of apoptosis in various malignant tumours
1,2. Early therapy-
induced changes in tracer uptake correlate well with the therapy outcome and therefore could be used 
to predict therapy outcome on a patient-to-patient basis within 48 hours after the start of treatment. 
However, moderate tumour-to-background ratio and therapy-induced changes in normal tissues could 
confound image analysis. Accurate interpretation of Annexin V scans requires awareness of the bio-
physiological and biochemical properties contributing to the tracer distribution. Knowledge of common 
patterns and pitfalls associated with Annexin V imaging in combination with image corregistration 
(SPECT/CT) can make this modality more valuable for evaluation of responses to anticancer therapy.
Role of Apoptosis in Oncology
Apoptosis is a key regulator of tissue homeostasis, which critically depends on the balance between the 
tissue proliferation and cell death compartments. Defects in apoptotic pathways are now known to con-
tribute to a wide range of human diseases, varying from neurodegenerative disorders to malignancies
3,4.
If disruption of the apoptosis process contributes to pathogenesis of cancer, then it is not surprising 
that existing anticancer agents work by triggering apoptosis
5,6,7. Recent studies demonstrated that most, 
if not all chemotherapeutic drugs and radiotherapy induce apoptosis in susceptible cell types.
Despite extremely complicated genetic regulation of apoptotic pathways, morphological cell changes 
are quite predictable. The morphological hallmarks of apoptosis are cell membrane blebbing, cytoplasm 
shrinkage, chromatin condensation and fragmentation into membrane-closed vesicles
8. These changes are 
accompanied by biochemical transformations, including externalisation of phosphatidylserine on the outer 
leaﬂ  et of the cell membrane
9. This process is one of the earliest events in the apoptosis cascade. It does 
not depend on the apoptosis-inducing agent or cell type, persists until the cell death programme is fully 
completed and promotes recognition of the apoptotic cells by phagocytes. Therefore, early exposure of 
phosphatidylserine constitutes an attractive biomarker for non-invasive in vivo imaging of apoptosis.
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Annexin V biophysiological 
and biochemical properties
Annexin V is a member of the annexin family of 
calcium and phospholipids binding family of pro-
teins
10. Like the other annexin proteins, it is widely 
expressed in eukaryotic organisms. It consists of 
319 amino acids, forming a single polypeptide 
chain with molecular weight of 35.7 kDA. It is 
folded into a planar cyclic arrangement with the 
NH2-terminal tail, unique for each Annexin, and 
COOH-protein terminal core domain, consisting 
of four homologous repeats of approximately 
70 amino acids. Every repeat contains a highly 
conserved sequence of 17 amino acids termed the 
endonexin loop, which harbours a characteristic 
Ca
2+ and phospholypid-binding site
11.
Most of the known biological activities of 
Annexin V are attributed to its high afﬁ  nity for 
12phosphatidylserine, it was labelled with ﬂ  uores-
cent and radionuclide tags and is now widely used 
for detection and quantiﬁ  cation of apoptosis both 
in vitro and in vivo.
99mTc-Hynic-rh-Annexin V Scintig-
raphy
Recombinant Annexin V labelled with 
99mTech-
netium by hydrazine-nicotinamide (HYNIC) 
method is so far the most widely investigated and 
extensively used tracer for in vivo visualisation 
of programmed cell death. It is successfully used 




inﬂ  ammation and hypoxic brain injury
16. Most 
interestingly it has shown great potential for in 
vivo monitoring of therapy-induced apoptosis in 
various malignant tumours as a predictor of 
therapy outcome
17,18,19.
99mTc-Hynic-rh-Annexin V scintigraphy is per-
formed 4 hours after the injection of 555–925 MBq 
(15–25mCi) of 
99mTc-labeled Annexin V to allow 
clearance of the radiotracer from the soft tissues, 
resulting in a higher tumour-to-background ratio. 
A gamma camera equipped with low-energy, high-
resolution collimator provides the best quality 
images. Standard acquisition includes anterior and 
posterior static whole body images, obtained with 
the matrix 1024 × 512 and SPECT of the region of 
interest acquired by the step-and-shoot mode, one 
step per 3 degrees, 30 seconds per frame, matrix 
size 128 × 128 × 16. For SPECT reconstructions 
an iterative algorithm and postﬁ  ltering using a 
Butterworth ﬁ  lter (cut off frequency 0.35, order 5) 
are recommended.
The time interval between the initiation of 
therapy and early posttreatment scan can be a 
critical point for correct interpretation of the 
tumour uptake changes. Currently posttreatment 
scans are performed between 4 and 48 hours after 
the start of treatment and depends on both the 
tumour morphology and treatment modality.
General Interpretation Issues
99mTc-Hynic-rh-Annexin V binds selectively to 
phosphatidylserine (PS) residuals in the presence 
of Ca
2+ ions independently of the apoptosis-
inducing agent or cell type. After intravenous 
injection it is distributed with the bloodstream and 
binds to the apoptotic cells or cell debris in normal 
tissues and tumours. Imaging is typically started 
at least four hours after injection to allow sufﬁ  cient 
blood pool clearance. Normal physiologic uptake 
is seen in the liver, spleen, and bone marrow. 
Because of predominantly renal clearance, intense 
accumulation is always seen in renal parenchyma, 
collecting system and bladder
20. Normal distribu-
tion of 
99mTc-Hynic-rh-Annexin V is illustrated on 
Figure 1.
Figure 1. Normal distribution of 
99mTc-Hynic-rh-Annexin VPlanar 
anterior (A) and posterior (B) images, obtained 4 hours after intra-
venous injection of the radiofarmacon demonstrate physiological 
tracer accumulation in the liver, kidneys, bladder and bone 
marrow.
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Annexin V Uptake in Various 
Malignancies
It is widely accepted that therapy-induced changes 
in Annexin V tumour uptake, detected shortly 
after the start of anticancer treatment correlate 
well with therapy outcome in various malignant 
tumours. In our previous publications we reported 
the pattern of the tracer uptake in low grade 
lymphomas, non-small cell lung cancer (NSCLC) 
and head and neck squamous cell carcinoma. In 
general, therapy-induced increase of the tumour 
uptake within 48-hours after the start of treatment 
correlated with favourable response, stable or 
decreased tracer accumulation indicated stable 
disease or progression. Interestingly, the pattern 
of Annexin V tumour uptake depended to a large 
extent on tumour morphology and treatment 
regimen. Low grade lymphomas, highly radio-
sensitive tumours, responding to radiotherapy 
predominantly through therapy-induced apopto-
sis
21, served in this context a perfect model to 
study the feasibility of in vivo monitoring of 
apoptosis in malignancies. In 26 patient with low 
grade lymphomas we have observed moderate 
baseline tracer accumulation with a prominent 
increase of uptake in responding tumours
22. In 
contrast, patients with NSCLC show low or absent 
uptake before the start of treatment with less 
prominent, however significant increase in 
responders
23. The groups of Belhocine
17 and van 
de Wiele
24,25 had demonstrated similar pattern of 
tracer uptake in breast cancer, bladder and 
oesophageal cancer.
Thus the general pattern of therapy-induced 
tumour uptake changes in malignant tumours 
seems to be constant. Therapy-induced increase of 
tracer uptake correlates with favourable outcome, 
stable or decreased uptake—with stable disease or 
progression, however the intensity and grade of 
tracer uptake could vary depending on tumour 
morphology.
Speciﬁ  c Interpretation Issues
Tumour uptake
Annexin V accumulation before the start of treat-
ment represents a combination of spontaneous 
apoptosis and necrosis as part of tumour cell 
turnover. Consequently, tracer accumulations 
outside the known tumour sites or areas of 
physiological uptake on the total body and SPECT 
could indicate unknown tumour localisations as 
illustrated on Figure 2.
Tumour uptake evaluation could be compro-
mised by intense tracer accumulation in the sur-
rounding normal tissues. This phenomenon is of 
high importance for the evaluation of the posttreat-
ment scans, when normal tracer distribution is 
disturbed by therapy-induced increase of uptake 
in the salivary glands and bone marrow.
Introduction of such hybrid SPECT/CT systems 
has addressed this problem; however in absence 
of hybrid systems, accurate software based match-
ing could deliver additional information about the 
tumour localisation and its relation with normal 
structures.
Tracer uptake in benign 
(or non-malignant) lesions
Increased Annexin V uptake can be observed in 
many benign processes, including inﬂ  ammation 
and infectious diseases (pneumonia, phlebitis), 
instable atherosclerotic plaques. Another possible 
Figure 2. Tumour localisation A 79-year old male with low grade 
follicular lymphoma in lymph nodes on the left side of the neck. 
Coronal baseline (A) and early posttreatment (B) Annexin V SPECT 
images show pathological tracer accumulation in the nasopharynx 
left (black arrows). This lesion correlates with the solid mass on axial 
T1-weighted (C) and contrast-enhanced T1-weighted (D) MR images 
(white arrows). Histological examination revealed the diagnosis of 
low grade follicular lymphoma.Note radiotherapy-induced increase 
of the tracer uptake in the irradiated neck lymph nodes on the early 
posttreatment scan (B).
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pitfall we have observed was the tracer accumulation 
in capillary haemangioma.
Infection and inﬂ  ammation
Infectious foci contain both necrotic and apoptotic 
cells, thus providing the substrate for Annexin V 
binding as illustrated in Figure 3.
Thrombosis and thrombophlebitis
Annexin V was first introduced as a platelet-
directed thrombus-targeting agent. In vivo visu-
alisation of acute platelet-rich thrombi by means 
of Annexin V scintigraphy is widely discussed in 
the literature
26,27,28.Tracer afﬁ  nity to PS exposed 
on the surface of activated platelets explains tracer 
accumulation on the compromised vessels. This 
phenomenon as well as PS exposure on the inﬂ  am-
matory cells may be responsible for tracer 
accumulation at sites of thrombophlebitis after the 
intravenous infusion of cisplatin en gemcitabine 
as illustrated in Figure 4.
Atherosclerosis
Annexin V accumulation in atherosclerotic plaques 
is suggested to represent plaque instability and may 
be used to identify patients at risk for acute vascu-
lar events
29. Apoptosis of smooth-muscle cells and 
of macrophages in the plaque is thought to cause 
this tracer accumulation. This phenomenon is 
responsible for another pitfall of Annexin V inter-
pretation in oncology, especially in patients with 
head and neck tumours. As illustrated in Figure 5, 
the radiofarmacon accumulation in the unstable 
plaque in carotid artery could mimic lymph node 
involvement.
Haemangioma
Haemangioma is a common benign vascular neo-
plasm that closely resembles normal vessels and 
that can be found in all organs of the human body. 
Figure 3. A 52-year old man with NSCLC and post-obstructive pneu-
monia in the right upper lobe (white arrows) on contrast-enhanced 
CT (A) which shows intense tracer uptake (white arrows) in the 
baseline Annexin V SPECT (B).
Figure 4. Baseline (A) and post-treatment (B) planar Annexin V 
images obtained 24 hours after the ﬁ  rst injection of cisplatin in the 
right elbow show linear increased tracer uptake in the projection of 
the vena basilica, corresponding with the presence of phlebitis.
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The mechanism of the Annexin V accumulation in 
haemangioma is not completely clear yet, however 
it is suggested that spontaneous apoptosis in the 
endothelial cells, reﬂ  ecting involuntary changes in 
the lesion, could be responsibly for this phenom-
enon as illustrated in Figure 6.
Annexin V scan interpretation after 
chemotherapy or radiotherapy
Anticancer treatment causes prominent changes 
in tumour tracer accumulation and affects tracer 
distribution in normal tissues. Both early and late 
therapy induced changes could inﬂ  uence tracer 
distribution in normal tissues. The most promi-
nent changes occur in salivary glands and bone 
marrow. As reported in our previous publication, 
salivary glands show intense increase of tracer 
accumulation conﬁ  ned to the radiation ﬁ  eld. It 
could represent radiation-induced apoptosis in the 
serous gland cells as demonstrated by Stephens 
et al 
30. Tracer uptake may carry prognostic infor-
mation for the early evaluation of the salivary 
gland damage and function. Annexin V scans 
performed in patients with a history of salivary 
gland irradiation showed minor tracer accumula-
tion in the irradiated glands without any changes 
of uptake after the radiotherapy as shown in 
Figure 7. These ﬁ  ndings probably illustrate irre-
versible radiotherapy-induced damage of the 
serous gland cells and may be a useful biomar-
ker of radiation-induced salivary dysfunction. 
Early radiotherapy induced tracer uptake com-
promises tumour uptake evaluation in head and 
neck area, as illustrated on Figure 8.
Chemotherapy and radiotherapy-induced 
bone marrow tracer accumulation could reﬂ  ect 
intramedullary apoptosis of haematopoietic tissue. 
As shown by Blankenberg et al, increase of 
Annexin V uptake in the bone marrow shortly after 
the start of chemotherapy, correlated with decrease 
in marrow cellularity affecting white and red blood 
cell nuclei with increasing atypia and nuclear 
fragmentation (apoptosis)
31. These ﬁ  ndings could 
explain diffuse increase of the tracer accumulation 
in the bone marrow of patients, receiving cisplatin 
and/or radiotherapy.
Absence of tracer uptake in previously irradiated 
bone marrow could, thus be related to different 
radiosensitivity and (Figure 9) regrowth potential 
of the stromal and haemopoietical components with 
rapid regeneration of stromal tissue and replacement 
of the haemopoetical cells by adipocytes.
Summary
Sequential evaluation of early therapy-induced 
apoptosis is a promising method to predict tumour 
response within 48 hours after the start of treatment 
in various malignant tumours. Therapy-induced 
increase of the tracer uptake correlates well with 
short-term outcome, decrease or stable tracer 
uptake is characteristic for unfavourable prognosis. 
Figure 5. Planar (A) and Annexin V SPECT (B) images show patho-
logical tracer uptake in the left side of the neck (black arrows), cor-
responding with prominent stenosis of the left carotid artery (white 
arrows) in the sagital (C) and frontal (D) MIP from MR angiography.
Figure 6. Planar anterior (A) and lateral (B) Annexin V images show 
focal tracer uptake in the skull right. This lesion correlates with an 
oval subcutaneous mass with intermediate signal intensity on T1 
weighted MR image and homogeneous enhancement on coronal (D) 
and axial gadolinium-enhanced T1-weighted MR images, identiﬁ  ed 
as a capillary hemangioma.
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Intensity and time-window for apoptosis imaging 
varies from tumour type and therapy regimen. 
Moreover, tumour uptake evaluation could be 
compromised by tracer accumulation in normal 
structures and non-malignant lesions. Knowledge 
of pattern of tracer uptake and recognition of the 
pitfalls of Annexin V-based apoptosis imaging 
could improve accurate identiﬁ  cation and interpre-
tation of tracer uptake to allow patient-tailored 
therapy.
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